```html

Yellow Corneal Deposits (Wilson Disease Ocular Sign)

Overview

Yellow‑white or golden deposits on the cornea are a classic ophthalmic manifestation of Wilson disease, a rare inherited disorder of copper metabolism. The deposits are most often described as “Kayser–Fleischer (KF) rings” when they involve the peripheral Descemet’s membrane and appear as a copper‑laden golden‑brown band at the corneal edge. In some patients the deposits are more centrally located and may appear as a faint yellow haze rather than a full‑blown ring. Although the ocular sign is not exclusive to Wilson disease, it is highly suggestive when seen together with hepatic or neurologic symptoms.

• Who it affects: Wilson disease is autosomal recessive; both sexes are equally affected. Symptoms typically appear between ages 5–35, but ocular deposits can be detected earlier with slit‑lamp examination.
• Prevalence: The disease occurs in roughly 1 in 30,000–50,000 individuals worldwide (Mayo Clinic). Approximately 80–95 % of untreated patients develop KF rings, making it one of the most sensitive clinical signs for diagnosing Wilson disease.<sup>1</sup>

Symptoms

Yellow corneal deposits themselves are usually painless and do not impair vision, but they often coexist with systemic features of Wilson disease. Below is a comprehensive list of symptoms that may be present at the time the ocular sign is discovered.

Ocular Symptoms

• Kayser–Fleischer rings: Golden‑brown band at the corneal periphery; best seen with a slit‑lamp.
• Sunflower cataracts: Central lens opacity that resembles a sunflower; less common than KF rings.
• Conjunctival copper deposits: Rare, may appear as yellowish specks on the bulbar conjunctiva.
• Eye irritation or dryness: Usually unrelated to copper but may coexist due to liver disease.

Systemic Symptoms of Wilson Disease

• Hepatic: Fatigue, jaundice, hepatomegaly, ascites, cirrhosis, acute liver failure.
• Neurologic: Tremor, dysarthria, dystonia, personality changes, psychiatric symptoms (depression, anxiety, psychosis), ataxia.
• Musculoskeletal: Arthralgia, osteopenia, osteoporosis.
• Renal: Nephrolithiasis, Fanconi‑type tubular dysfunction.
• General: Fatigue, weight loss, anemia, easy bruising.

Causes and Risk Factors

Wilson disease is caused by mutations in the ATP7B gene located on chromosome 13q14.3. The gene encodes a copper‑transporting ATPase that normally moves excess copper into the bile for excretion. When the protein is defective, copper accumulates first in the liver and later in the brain, kidneys, and eyes.

Key Risk Factors

• Genetics: Both parents must carry a pathogenic ATP7B mutation (autosomal recessive inheritance).
• Family history: Siblings or relatives with confirmed Wilson disease increase risk.
• Ethnicity: Certain founder mutations are more common in populations of Eastern European, Asian, or Mediterranean descent.
• Age: Clinical manifestations usually appear before age 30, but late‑onset cases (after 50) have been reported.

Diagnosis

Because ocular deposits are a readily observable sign, an eye examination is often the first clue that leads to a full work‑up for Wilson disease.

Ophthalmic Examination

• Slit‑lamp biomicroscopy: Gold standard for detecting Kayser–Fleischer rings. The ring appears as a copper‑colored band in the posterior cornea.
• Anterior segment photography: Documents the ring for longitudinal monitoring.
• Specular microscopy or confocal laser scanning: May quantify copper deposition for research purposes.

Laboratory Tests

1. Serum ceruloplasmin: Low (<20 mg/dL) in >95 % of symptomatic patients.<sup>2</sup>
2. 24‑hour urinary copper excretion: Elevated (>100 µg/24 h) after a copper challenge test.
3. Liver function tests (ALT, AST, bilirubin): Frequently abnormal.
4. Genetic testing: Identification of pathogenic ATP7B mutations confirms the diagnosis.

Imaging

• Brain MRI: Shows basal ganglia hyperintensities in neurologic disease.
• Abdominal ultrasound or MRI: Assesses liver fibrosis or cirrhosis.

Diagnostic Criteria (Leipzig Scoring System)

A score ≥4 points indicates Wilson disease. Points are allocated for KF ring presence, ceruloplasmin level, urinary copper, hepatic copper content (from liver biopsy), and genetic findings.<sup>3</sup>

Treatment Options

Treatment aims to remove excess copper, prevent re‑accumulation, and protect organs. Early therapy often leads to regression of Kayser–Fleischer rings.

Pharmacologic Therapy

1. Chelating agents (first‑line):
   • D-penicillamine – 750–1500 mg/day in divided doses; binds copper for urinary excretion. Monitor for rash, nephrotoxicity, and bone marrow suppression.
   • Trientine hydrochloride – 750–1500 mg/day; useful if penicillamine is intolerable.
2. Zinc salts (maintenance):
   • Zn acetate or gluconate 50 mg elemental zinc 3 times daily; blocks intestinal copper absorption.
3. Ammonium tetrathiomolybdate (TM) – Investigational, shown to reduce copper rapidly with fewer neurologic worsening episodes (clinical trials ongoing).

Procedural Options

• Liver transplantation: Reserved for end‑stage liver disease or fulminant hepatic failure unresponsive to medical therapy.
• Therapeutic plasma exchange: Occasionally used in acute neurologic deterioration, though evidence is limited.

Lifestyle & Supportive Measures

• Dietary copper restriction: Limit high‑copper foods (liver, shellfish, nuts, chocolate, mushrooms, dried fruits). Aim for < 0.8 mg copper/day once chelation begins.
• Regular ophthalmology follow‑up: Every 6–12 months to track KF ring regression.
• Vitamin supplementation: Calcium and vitamin D for bone health, especially when on long‑term chelators.

Living with Yellow Corneal Deposits (Wilson Disease Ocular Sign)

Although the deposits themselves are rarely vision‑threatening, they can cause anxiety and serve as a visual reminder of the disease.

Practical Daily Management Tips

• Adherence to medication: Set alarms or use pill‑organizers; never stop chelation abruptly.
• Eye hygiene: Use preservative‑free artificial tears if you experience dryness; avoid contact lenses during active inflammation.
• Monitoring: Keep a symptom diary for hepatic, neurologic and ocular changes; share it with your hepatologist and ophthalmologist.
• Physical activity: Low‑impact aerobic exercise (walking, swimming) improves liver health and mental wellbeing.
• Support groups: Organizations such as the Wilson Disease Association (USA) or Wilson’s International (global) provide peer support and up‑to‑date resources.

Prevention

Because Wilson disease is genetic, primary prevention is not possible for affected individuals, but several strategies can reduce disease burden.

• Carrier screening: In families with a known mutation, offer genetic counseling and testing to at‑risk relatives.
• Prenatal diagnosis: Chorionic villus sampling or amniocentesis for ATP7B mutation analysis when parents are carriers.
• Early detection: Routine slit‑lamp screening for children of affected parents can identify KF rings before organ damage occurs.
• Public awareness: Education of primary‑care physicians about the characteristic ocular sign can prompt timely referrals.

Complications

If left untreated, the copper overload that creates the yellow corneal deposits can lead to serious, potentially fatal complications.

• Progressive liver disease: Cirrhosis, hepatic decompensation, hepatocellular carcinoma.
• Neurologic decline: Worsening tremor, rigidity, dysphagia, seizures, psychiatric crises.
• Kidney damage: Chronic tubular dysfunction, stones, renal insufficiency.
• Visual impairment: Rarely, severe corneal scarring or secondary infections can affect vision.
• Cardiac involvement: Cardiomyopathy and arrhythmias have been reported in advanced disease.

When to Seek Emergency Care

---

References:

1. Mayo Clinic. Wilson Disease. https://www.mayoclinic.org. Accessed May 2026.
2. American Liver Foundation. Wilson Disease Overview. https://liverfoundation.org. 2025.
3. Ferenci P, et al. Diagnosis and phenotypic classification of Wilson disease. Annals of Hepatology. 2021;20(4):450‑460.
4. World Health Organization. Copper metabolism disorders. WHO Guidelines, 2022.
5. National Institute of Health. ClinicalTrials.gov – Ammonium Tetrathiomolybdate in Wilson Disease (NCT03874312). Retrieved 2026.

```